In summary, we have reported the ability of tumor-intrinsic S100A1 blockade to remodel the immunologically “cold” TME into an inflamed and immunoactive phenotype, eliciting antitumor immunity and potentiating cancer immunotherapy. The gene discussed is S100A1; the disease is cancer.